Experience in the use of collagenase clostridium histolyticum in the management of Peyronie’s disease: current data and future prospects | Zendy

María Alejandra Egui Rojo | Zendy; I. Moncada Iribarren | Zendy; Joaquı́n Carballido | Zendy; Juan Ignacio MartínezSalamanca | Zendy

Open Access

Experience in the use of collagenase clostridium histolyticum in the management of Peyronie’s disease: current data and future prospects

Author(s) -

María Alejandra Egui Rojo,

I. Moncada Iribarren,

Joaquı́n Carballido,

Juan Ignacio MartínezSalamanca

Publication year - 2014

Publication title -

therapeutic advances in urology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.115

H-Index - 30

eISSN - 1756-2880

pISSN - 1756-2872

DOI - 10.1177/1756287214537331

Subject(s) - peyronie's disease , medicine , penile curvature , tunica albuginea (penis) , food and drug administration , collagenase , adverse effect , penis , clinical trial , disease , urology , scar tissue , surgery , intensive care medicine , pharmacology , biochemistry , chemistry , enzyme

Peyronie's disease (PD) is a chronic wound-healing disorder characterized by formation of fibrous inelastic scarring of the tunica albuginea resulting in a variety of penile deformities. In most cases, PD is accompanied by a physical and psychological impact. Xiaflex® is an injectable collagenase clostridium histolyticum (CCh) preparation consisting of a predetermined mixture of two distinct collagenases. Recently the US Food and Drug Administration (FDA) approved Xiaflex® for the nonsurgical treatment of men with PD with curvature of 30° or more and tangible scar tissue plaque in their penis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research